Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment

Daniela Andreina Terribile, Riccardo Masetti, Gianluca Franceschini, Antonio Franco, Annamaria Martullo, Armando Orlandi, Stefano Magno, Alba Di Leone, Francesca Moschella, Maria Natale, Elena Jane Mason, Flavia De Lauretis, Fabio Marazzi, A. M. Sanchez, S. D'archi, L. Scardina

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Sentinel lymph node biopsy (SLNB) following neoadjuvant treatment (NACT) has been questioned by many studies that reported heterogeneous identification (IR) and false negative rates (FNR). As a result, some patients receive axillary lymph node dissection (ALND) regardless of response to NACT, leading to a potential overtreatment. To better assess reliability and clinical significance of SLNB status on ycN0 patients, we retrospectively analyzed oncological outcomes of 399 patients treated between January 2016 and December 2019 that were either cN0-ycN0 (219 pa-tients) or cN1/2-ycN0 (180 patients). The Endpoints of our study were to assess, furthermore than IR: oncological outcomes as Overall Survival (OS); Distant Disease Free Survival (DDFS); and Regional Disease Free Survival (RDFS) according to SLNB status. SLN identification rate was 96.8% (98.2% in patients cN0-ycN0 and 95.2% in patients cN+-ycN0). A median number of three lymph nodes were identified and removed. Among cN0-ycN0 patients, 149 (68%) were confirmed ypN0(sn), whereas regarding cN1/2-ycN0 cases 86 (47.8%) confirmed an effective downstaging to ypN0. Three year OS, DDFS and RDFS were significantly related to SLNB positivity. Our data seemed to confirm SLNB feasibility following NACT in ycN0 patients, furthermore reinforcing its predictive role in a short observation timing.
Lingua originaleEnglish
pagine (da-a)1-13
Numero di pagine13
RivistaJournal of Personalized Medicine
Volume11
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Breast cancer
  • Locally advanced breast cancer
  • Systemic treatment
  • Neoadjuvant chemotherapy
  • Sentinel lymph node
  • Mini-invasive treatment

Fingerprint Entra nei temi di ricerca di 'Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment'. Insieme formano una fingerprint unica.

Cita questo